Universal Biosensors Inc   (UBI)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 212
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Universal Biosensors Inc
Universal Biosensors Inc is a medical technology company that specializes in the development and commercialization of diagnostic tests and biosensor technology. The company is focused on creating innovative and cost-effective products for the medical industry, particularly in the areas of blood glucose monitoring, coagulation testing, and infectious diseases detection. Universal Biosensors aims to improve patient outcomes by providing accurate and reliable diagnostic solutions to healthcare professionals and patients worldwide.

   Company Address: 1 Corporate Avenue, Rowville 3178
   Company Phone Number: 3 9213 9000   Stock Exchange / Ticker: UBI


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Universal Biosensors Inc

Universal Biosensors Inc sees significant improvement in earnings, signaling a strong turnaround for the medical equipment & supplies company

Universal Biosensors Inc, a company specializing in medical equipment and supplies, has shown promising growth in the October to December 31, 2023 interval. The company managed to turn a profit with earnings per share (EPS) of $0.02 per share, a significant improvement from the EPS of $-0.05 a year ago. Additionally, the earnings per share turned positive from $-0.01 per share in the prior quarter. This turnaround in earnings is a positive sign for investors and indicates a strong performance by Universal Biosensors Inc.
Despite the positive earnings, the revenue for the company remained unchanged at $0.00 million from $0.76 million in the same quarter a year ago and sequentially from $1.92 million. However, the net shortfall decreased to $0.000 million from $-12.650 million in the similar quarter a year ago. This improvement in the net shortfall shows that the company is moving towards financial stability.

Universal Biosensors Inc

Universal Biosensors Inc Shines with Outstanding Performance in Sept 30, 2023 Fiscal Report

Universal Biosensors Inc, a leading Medical Equipment & Supplies company, recently released its financial results for the fiscal time-frame ending September 30, 2023. The company reported a remarkable revenue increase of 181.659% year on year, reaching $1.92 million. Despite incurring a loss of $-0.01, Universal Biosensors is generating positive market traction. In this article, we will analyze the impact of these financial results on the company's future prospects.
Solid Revenue Growth:
Universal Biosensors Inc's revenue growth of 181.659% demonstrates the company's ability to attract customers and expand its market share. The significant rise in revenue aligns well with the 0.57% top-line increase experienced by the Medical Equipment & Supplies sector during the same period. This suggests that Universal Biosensors' success is not an isolated case but reflects the positive trend within the industry.

Universal Biosensors Inc

UBI Bounces Back with Positive Earnings Amid Slight Revenue Dip in Q2 2023

Universal Biosensors Inc is a biotechnology company that focuses on the development and commercialization of cutting-edge biosensor technology. The company has made significant strides in recent years, as evidenced by its positive financial performance in the fiscal second quarter of 2023.
One of the key highlights of Universal Biosensors Inc's financial results is the turnaround in earnings. The company reported earnings per share (EPS) of $0.01 in the second quarter, compared to a loss of $0.02 per share in the same period the previous year. This is a significant improvement and indicates the company's ability to generate profit and increase shareholder value.

Universal Biosensors Inc

Universal Biosensors Inc defies market turbulence with impressive rebound in Q1 2023

The stock market has been experiencing some turbulent times, with companies struggling to maintain their financial standing in the face of unexpected economic fluctuations. However, amidst all this chaos, Universal Biosensors Inc has managed to stay afloat, showing an improvement in its financial performance in the most recent quarter.
While Universal Biosensors Inc recorded a cumulative net loss of $-26 million during the 12 months leading up to the first quarter of 2023, the company has been able to reduce its loss per share to $-0.02 in comparison to last year's figure of $-0.03. Additionally, Universal Biosensors Inc saw a significant uptick in EPS from $-0.05 per share in the previous quarter.
Despite the healthcare sector being home to 461 other companies with a higher return on assets (ROA), Universal Biosensors Inc has been able to improve its overall ranking in the Mar 31 2023 quarter. Ranking at 2907 in ROA, up from 4619 in the previous quarter, Universal Biosensors Inc is definitely moving in the right direction.
The first quarter of 2023 also saw Universal Biosensors Inc report a net deficit of $-3.789 million, a notable improvement from the previous year's deficit of $-4.531 million. Revenue did take a hit, with a 24.823% decrease to $1.30 million from $1.72 million in the same quarter a year ago. However, there was a sequential revenue surge of 70.187%, from $0.76 million.


Universal Biosensors Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com